Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.

Treatment for multiple myeloma has evolved significantly, with long-term survival increasingly within reach for many patients ...

New research showcases the potential of plant-based diets in the prevention of multiple myeloma and gastrointestinal cancers.